TEVA Q3 2019 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.3B-5.9% YoY

Gross Profit

$1.8B42.9% margin

Operating Income

-$81M-1.9% margin

Net Income

-$314M-7.4% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$325M

Free Cash Flow

$156M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$57.2B

Total Liabilities

$42.3B

Stockholders' Equity

$13.8B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.3B	$4.5B	-5.9%
Gross Profit	$1.8B	$2.0B	-9.5%
Operating Income	-$81M	$16M	-606.3%
Net Income	-$314M	-$208M	-51.0%

Revenue Segments

International Markets

$736M70%

Other Activities

$314M30%

Geographic Segments

North America

$1.7B59%

Europe

$1.2B41%